Form 4: IOVA Interim CEO Vogt Reports RSU Vesting, Tax Withholding

IOVANCE BIOTHERAPEUTICS' Interim CEO, Frederick G. Vogt, reported the vesting of restricted stock units and subsequent share withholding for tax obligations.

Summary

• Frederick G. Vogt, Interim CEO and General Counsel of IOVANCE BIOTHERAPEUTICS, Inc. (IOVA), reported transactions related to his beneficial ownership.
• On March 2, 2026, 52,087 shares of common stock were acquired upon the vesting of restricted stock units (RSUs).
• Concurrently, 22,809 shares of common stock were disposed of at a price of $3.79 per share to satisfy mandatory tax withholding requirements related to the RSU vesting. This was not an open market sale.
• Following these transactions, Mr. Vogt directly beneficially owns 493,800 shares of common stock.
• Derivative securities transactions included the vesting of 41,669 RSUs (from a March 1, 2024 grant), leaving 166,675 RSUs from that specific grant.
• Additionally, 10,418 RSUs (from a March 2, 2023 grant) vested, resulting in 0 RSUs remaining from that specific grant.
• Each RSU represents a contingent right to receive one share of the Issuer's common stock.
• Remaining RSUs will vest in equal quarterly installments.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing a routine executive compensation transaction with no significant positive or negative implications for the company's operational or financial performance.

Positives

• The vesting of 52,087 restricted stock units indicates continued compensation for the Interim CEO, aligning his interests with shareholders.
• The acquisition of shares through RSU vesting increases the Interim CEO's direct ownership in the company.

Negatives

• 22,809 shares were disposed of to cover tax obligations, which is a standard practice but reduces the direct share count.

Future Outlook

Remaining Restricted Stock Units held by Frederick G. Vogt are scheduled to vest in equal quarterly installments.

Industry Context

StockSavvy.ai notes that routine executive compensation events like RSU vesting and subsequent tax withholding are common across the biotechnology and pharmaceutical industries, reflecting standard practices for incentivizing and retaining key leadership.

Comparison to Industry Standards

• StockSavvy.ai observes that the mechanism of RSU vesting and share withholding for tax purposes is a standard compensation practice widely adopted by publicly traded companies, including peers in the biotech sector such as Gilead Sciences, Amgen, and Regeneron Pharmaceuticals.
• The reported transaction price of $3.79 for tax withholding is specific to the company's stock price on the transaction date and not directly comparable as a performance metric to other companies' stock prices.

Related Party Transactions

• The disposition of 22,809 shares for tax withholding purposes is a transaction with the Issuer (IOVANCE BIOTHERAPEUTICS, INC.) to satisfy mandatory tax obligations upon RSU vesting.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine compensation event, but it reflects ongoing executive alignment through equity ownership.
• Employees: No direct impact on general employees.
• Management: Frederick G. Vogt's equity stake is adjusted, reflecting vested compensation and continued alignment with company performance.

Next Steps

• Remaining Restricted Stock Units held by Frederick G. Vogt will vest in equal quarterly installments.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event involving RSU vesting and tax withholding. It does not provide new fundamental information about the company's operations, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, as the filing itself does not present a compelling reason to buy or sell the stock based solely on this information.

Keywords

IOVANCE BIOTHERAPEUTICS, IOVA, Frederick G. Vogt, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Stock Ownership, Executive Compensation, Tax Withholding